Last reviewed · How we verify

NCT06875778

Development & Validation of Pregnancy Specific Pelvic Floor Rehab Protocol

Completed NA Last updated 19 August 2025
What this trial tests

NA trial testing Pelvic Floor Exercises in Pelvic Floor Disorder in 15 participants. Completed in 30 July 2025.

Timeline
11 February 2024
Primary endpoint
1 April 2025
30 July 2025

Quick facts

Lead sponsorRiphah International University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment15
Start date11 February 2024
Primary completion1 April 2025
Estimated completion30 July 2025
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Riphah International University

Who can join

Adults 18 to 40, female only, with Pelvic Floor Disorder or Pelvic Floor Muscle Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pelvic Floor Weakness is very common Facing by women during Pregnancy. PFM weakness is recognized as one of the problems encountered in patients with urinary and fecal incontinence which have very negative impact on Quality of life of Patients. This project aims to design, implement, and validate a pelvic floor rehabilitation protocol specifically for pregnant individuals.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Pelvic Floor Exercises

Trials testing the same drug.

Other recruiting trials for Pelvic Floor Disorder

Currently open trials in the same condition.

Other Riphah International University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06875778.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing